Table 3 Logistic regression models predicting overall change in CD4 + T cell count of adults during ART
From: Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children
Variables | aRisk of non-response | bRisk of failure to attain >200 CD4 cell | |||
|---|---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | ||
Sex | Female | 0.2 (0.65-0.658) | 0.08 | 6.5 | |
Male | 0.4 (0.16-1.33) | 0.150 | |||
Age (years) | <29 | 0.76 | 0.52 | ||
30-39 | 1.68 (0.401-7.09) | 0.47 | 14.0 (1.62-122.7) | 0.160 | |
≥40 | 1.17 (0.32-4.21) | 0.81 | 1.88 (0.60-5.90) | 0.278 | |
WHO Clinical Stage I | I | 0.69 | 0.4 | ||
II | 0.154 (0.007-3.57) | 0.244 | 0.038 (0.002-0.894) | 0.045 | |
III | 0.346 (0.027-4.418 | 0.414 | 0.769 (0.043-13.866) | 0.8 | |
IV | 0.359 (0.043-3.013) | 0.345 | 0.325 (0.039-2.7) | 0.32 | |
Haematocrit value | < 37% | 3.0 | 3.0 | ||
≥ 37% | 2.54 (0.848-7.514) | 0.096 | 2.16 (0.751-6.253) | 0.153 | |
ART regimen | |||||
3TC + d4T + NVP | 1.66 (0.349-7.9) | 0.542 | 4.857 (0.974-24.227) | 0.054 | |
3TC + d4T + EFV | 1.87 (0.36-9.64) | 0.450 | 2.286 (0.50-10.44) | 0.286 | |
3TC + AZT + NVP | 6.00 (0.53-67.27) | 0.146 | 2.667 (0.463-15.35) | 0.272 | |
3TC + AZT + EFV | 0.54 | 0.288 | |||
CD4+ T cell count | <50 | 0.313 | 0.99 | ||
50-99 | 2.00 (0.174-22.94) | 0.578 | 0.578 0.99 (0.00-) | 0.9 | |
100-199 | 9.20 (0.91-93.02) | 0.060 | 0.060 0.99 (0.00-) | 0.9 | |
200-349 | 1.68 (0.436-6.47) | 0.451 | 0.451 0.99 (0.00-) | 0.9 | |